Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023

On May 30, 2023 Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, reported that the Company will present at several healthcare industry conferences in June 2023 (Press release, Carisma Therapeutics, MAY 30, 2023, View Source [SID1234632230]). These conferences include:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting

Yara Abdou, MD, will present trials in progress poster during the meeting:
A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors
Saturday, June 3, 2023, at 8:00 am CT
Chicago, Illinois

2023 Fierce Biotech Next Gen Virtual Event

Michael Klichinsky, Pharm.D., Ph.D., Co-Founder & Chief Scientific Officer will give a presentation on Carisma’s revolutionary CAR-M approach.
Tuesday, June 13, 2023 at 10:00 am ET
Virtual
Register to view webcast here.

CHI’s Immuno-Oncology Summit Europe

Tom Wilton, Chief Business Officer, will give a presentation titled "CAR-M: Driving Anti-Tumor Immunity with Chimeric Antigen Receptor Macrophages."
Wednesday, June 21, 2023, at 5:10 pm BST
London, United Kingdom

The Cell and Gene Therapy Conference

Michael Klichinsky, Pharm.D., Ph.D., Co-Founder & Chief Scientific Officer will give a presentation titled "Development of CAR macrophages – a novel approach for solid tumor immunotherapy."
Saturday, June 24, 2023 at 2:30 pm ET
King of Prussia, Pennsylvania
A replay of webcasts, when available, will be posted and archived at Carisma’s Investor Events webpage for a limited time following the event.